Transfusion in TAVR: Caution Is Best

Periprocedural red blood cell transfusion in transcatheter aortic valve replacement (TAVR) correlates with increased mortality and acute kidney injury. It also resulted an independent predictor of 30-day mortality, irrespective of bleeding and vascular complications. 

La prudencia es buena consejera para decidir una transfusión en el TAVI

The global trend that limits transfusion, in all procedures in general, has finally reached TAVR. 

The multicenter registry TRITAVI (Transfusion Requirements in Transcatheter Aortic Valve Implantation) retrospectively included patients undergoing transfemoral TAVR. Groups were compared using propensity score matching. 

Primary end point was mortality at 30 days, non-fatal MI and stroke. Among the secondary end points was acute kidney injury.

Propensity score took into account hemoglobin nadir, hemoglobin drop, and whether or not there were procedural complications, vascular complications, or major bleeding. 


Read also: SOLACI PERIPHERAL | 5th Clinical Case: Abdominal Aortic Aneurysm with Hostile Neck.


Of 2587 patients in the registry, 421 (16%) received transfusion. Primary end point occurred in 4% of patients in the general population, while MI rate was 0.4%, stroke 1.5% and acute kidney injury 4.8%.

After propensity score matching, 842 matched patients showed transfusion increased mortality by nearly 100% (HR: 2.07, CI 95%, 1.06 to 4.05; p=0.034) and increased acute kidney injury by a 4-fold (HR 4.35 CI 95%, 2.21 to 8.55; p<0.001).

Other variables, and the different subgroups, did not modify the impact of transfusion on events, resulting in completely independent predictors. As well as transfusion, vascular complications and major bleeding resulted independent predictors of mortality at 30 days. 

Conclusions

Red blood cell transfusion increased mortality at 30 days and acute kidney injury in the context of TAVR irrespective of major bleeding and vascular complications. 

Original Title: Early Adverse Impact of Transfusion After Transcatheter Aortic Valve Replacement. A Propensity-Matched Comparison From the TRITAVI Registry.

Reference: Marco Zimarino et al. Circ Cardiovasc Interv. 2020;13:e009026.  DOI: 10.1161/CIRCINTERVENTIONS.120.009026.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...